文献速递呼吸危重症与机械通气呼吸道感染

四环素抑制Caspase-1改善急性肺损伤

Inhibition of Caspase-1 with Tetracycline Ameliorates Acute Lung Injury.
PubMed 文献 · Am J Respir Crit Care Med · 2021-01-01

本研究探讨以IL-1β和IL-18表达为特征的ARDS亚型,并验证四环素抑制炎症小体-caspase-1通路的潜力。结果显示直接ARDS患者BALF中IL-1β和IL-18显著高于间接ARDS,四环素在小鼠模型中通过选择性抑制caspase-1依赖性IL-1β和IL-18产生减轻肺损伤和炎症、改善生存,并减少直接ARDS患者肺泡白细胞产生IL-1β和IL-18。提示四环素可能对caspase-1活性升高的直接ARDS患者有效。

要点

  • 直接ARDS患者BALF中IL-1β和IL-18显著高于间接ARDS。
  • 四环素在小鼠急性肺损伤中减轻肺损伤和炎症并改善生存。
  • 四环素减少直接ARDS患者肺泡白细胞IL-1β和IL-18产生。

核心结论

  • 四环素可能对caspase-1活性升高的直接ARDS患者有效。

研究设计与样本

  • 量化ARDS患者BALF中IL-1β和IL-18浓度。
  • 在两种直接(肺源性)急性肺损伤小鼠模型中评估四环素对肺损伤和炎症的影响。
  • 离体评估四环素对直接ARDS患者肺泡白细胞产生IL-1β和IL-18的影响。
  • 使用小鼠巨噬细胞进一步表征四环素对炎症小体-caspase-1通路的作用。
  • 临床试验注册号NCT04079426。

主要发现

  • 直接ARDS患者BALF中IL-1β和IL-18浓度显著高于间接(非肺源性)ARDS患者。
  • 在实验性急性肺损伤中,四环素通过选择性抑制caspase-1依赖性IL-1β和IL-18产生,显著减轻肺损伤和肺部炎症,并改善生存。
  • 四环素减少直接ARDS患者肺泡白细胞产生IL-1β和IL-18。

临床怎么用

  • 可考虑以IL-1β和IL-18表达识别直接ARDS中可能受益于四环素治疗的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Acute respiratory distress syndrome (ARDS) is a heterogeneous syndrome with a mortality of up to 40%. Precision medicine approaches targeting patients on the basis of their molecular phenotypes of ARDS might help to identify effective pharmacotherapies. The inflammasome-caspase-1 pathway contributes to the development of ARDS via IL-1β and IL-18 production. Recent studies indicate that tetracycline can be used to treat inflammatory diseases mediated by IL-1β and IL-18, although the molecular mechanism by which tetracycline inhibits inflammasome-caspase-1 signaling remains unknown. Objectives: To identify patients with ARDS characterized by IL-1β and IL-18 expression and investigate the ability of tetracycline to inhibit inflammasome-caspase-1 signaling in ARDS. Methods: IL-1β and IL-18 concentrations were quantified in BAL fluid from patients with ARDS. Tetracycline's effects on lung injury and inflammation were assessed in two mouse models of direct (pulmonary) acute lung injury, and its effects on IL-1β and IL-18 production were assessed by alveolar leukocytes from patients with direct ARDS ex vivo. Murine macrophages were used to further characterize the effect of tetracycline on the inflammasome-caspase-1 pathway. Measurements and Main Results: BAL fluid concentrations of IL-1β and IL-18 are significantly higher in patients with direct ARDS than those with indirect (nonpulmonary) ARDS. In experimental acute lung injury, tetracycline significantly diminished lung injury and pulmonary inflammation by selectively inhibiting caspase-1-dependent IL-1β and IL-18 production, leading to improved survival. Tetracycline also reduced the production of IL-1β and IL-18 by alveolar leukocytes from patients with direct ARDS. Conclusions: Tetracycline may be effective in the treatment of direct ARDS in patients with elevated caspase-1 activity. Clinical Trial registered with www.clinicaltrials.gov (NCT04079426).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Peukert K, Fox M, Schulz S, et al. Inhibition of Caspase-1 with Tetracycline Ameliorates Acute Lung Injury. Am J Respir Crit Care Med. 2021. PMID: 33760701. doi:10.1164/rccm.202005-1916OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。